Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union

Zevra Therapeutics announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the Marketing Authorization Application for arimoclomol to treat Niemann-Pick disease type C. The company plans to request a re-examination of the decision and continues supporting patient access through its Expanded Access Program.